Argenx SE (NASDAQ:ARGX) announced a significant leadership transition on Monday, appointing Chief Operating Officer Karen Massey as its new Chief Executive Officer and Executive Director, effective immediately.
The move marks a strategic evolution for the immunology powerhouse, with long-serving CEO Tim Van Hauwermeiren stepping down from daily operations to assume the role of Non-Executive Director and Chairman of the Board.
The succession plan is designed to ensure continuity as the company scales its commercial footprint.
Van Hauwermeiren, who has guided Argenx through its transformation from a clinical-stage startup to a global commercial biotech, will succeed Peter Verhaeghe as Chairman.
Verhaeghe is retiring after nearly two decades with the company, having served on the board since 2008.
Massey’s elevation to the top job places an operations veteran in charge as Argenx seeks to maximize the reach of its flagship product, Vyvgart, and advance its broader pipeline.
Her immediate appointment as CEO on January 5, 2026, allows her to take operational control while the governance formalities are finalized.
The board changes are subject to shareholder approval at the company’s Annual General Meeting scheduled for May 6, 2026.
The company indicated that the period between the announcement and the meeting will serve as a comprehensive transition phase, ensuring a smooth handover of board responsibilities.